Company news

Arcutis Biotherapeutics, Inc. news in 2024

Arcutis Biotherapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

December 15, 2024

Arcutis Announces Promotions on Executive Management Team

December 2, 2024

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

November 12, 2024

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

November 5, 2024

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

October 23, 2024

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

October 22, 2024

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

October 17, 2024

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

September 23, 2024

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

September 23, 2024

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

September 18, 2024

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

September 4, 2024

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

August 27, 2024

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 21, 2024

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

August 13, 2024

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

July 31, 2024

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

July 28, 2024

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

July 28, 2024

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

July 22, 2024

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

July 21, 2024

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

July 8, 2024

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

July 8, 2024

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 9, 2024

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 4, 2024

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 2, 2024

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

May 12, 2024

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

April 28, 2024

Arcutis Appoints David Topper as Chief Financial Officer

April 9, 2024

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 27, 2024

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

March 10, 2024

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

March 9, 2024

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

March 3, 2024

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

March 3, 2024

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

February 28, 2024

Arcutis Announces Proposed Public Offering

February 27, 2024

Arcutis Announces Pricing of $150 Million Public Offering

February 27, 2024

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

February 27, 2024

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 26, 2024

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

January 30, 2024

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

January 28, 2024

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

January 21, 2024

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

January 13, 2024

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

January 13, 2024

Calls in 2024

Decks in 2024